Tharimmune Inc. (THAR)
| Bid | 1.5 |
| Market Cap | 3.27M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -12.2M |
| EPS (ttm) | -9.41 |
| PE Ratio (ttm) | -0.16 |
| Forward PE | -2.32 |
| Analyst | Buy |
| Ask | 1.52 |
| Volume | 313,736 |
| Avg. Volume (20D) | 123,927 |
| Open | 1.76 |
| Previous Close | 1.73 |
| Day's Range | 1.51 - 1.89 |
| 52-Week Range | 0.95 - 6.45 |
| Beta | 1.20 |
About THAR
Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed c...
Analyst Forecast
According to 1 analyst ratings, the average rating for THAR stock is "Buy." The 12-month stock price forecast is $17, which is an increase of 996.77% from the latest price.
Stock Forecasts
2 days ago · accessnewswire.com
Tharimmune Appoints Clay Kahler and Gary Stetz to its Board of DirectorsBRIDGEWATER, NJ / ACCESS Newswire / April 30, 2025 / Tharimmune, Inc., (NASDAQ:THAR) ("Tharimmune" or the "Company") a clinical-stage biopharmaceutical company focused on developing innovative therape...
